Please use this identifier to cite or link to this item: https://hdl.handle.net/1/1883
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMonjur, Mohammad Riashad-
dc.contributor.authorSaid, Christian-
dc.contributor.authorBamford, Paul-
dc.contributor.authorParkinson, Michael-
dc.contributor.authorFord, Tom-
dc.contributor.otherSzirt, R-
dc.date.accessioned2020-10-20T23:07:03Z-
dc.date.available2020-10-20T23:07:03Z-
dc.date.issued2020-10-14-
dc.identifier.citation7(2):e001394en
dc.identifier.issn2053-3624en
dc.identifier.urihttps://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/1883-
dc.description.abstractOBJECTIVES: Determine whether an ultrathin biodegradable polymer sirolimus-eluting stent ('Orsiro'-BP-SES) has clinical benefits over second-generation durable polymer drug-eluting stents (DP-DES). METHODS: We conducted a prospective systematic review and meta-analysis of randomised clinical trials comparing Orsiro BP-SES against DP-DES (PROSPERO Registration: CRD42019147136). The primary outcome was target lesion failure (TLF): composite of cardiac death, target vessel myocardial infarction (TVMI) and clinically indicated target lesion revascularisation (TLR)) evaluated at the longest available follow-up. RESULTS: Nine trials randomised 11 302 patients to either Orsiro BP-SES or DP-DES. At mean weighted follow-up of 2.8 years, the primary outcome (TLF) occurred in 501 of 6089 (8.2%) participants with BP-SES compared with 495 of 5213 (9.5%) participants with DP-DES. This equates to an absolute risk reduction of 1.3% in TLF in favour of Orsiro BP-SES (OR 0.82; 95% CI 0.69 to 0.98; p=0.03). This was driven by a reduction in TVMI (OR 0.80; 95% CI 0.65 to 0.98; p=0.03). There were no significant differences in other clinical endpoints: cardiac death, TLR and stent thrombosis. CONCLUSION: The Orsiro BP-SES shows promising clinical outcomes in patients undergoing percutaneous coronary intervention compared with contemporary second-generation DES at a short to medium term follow-up. More research is warranted to evaluate performance over a longer follow-up period and in different clinical and lesion subsets.en
dc.description.sponsorshipCardiologyen
dc.subjectCardiologyen
dc.subjectHeart Diseaseen
dc.titleUltrathin-strut biodegradable polymer versus durable polymer drug-eluting stents: a meta-analysisen
dc.typeJournal Articleen
dc.identifier.doi10.1136/openhrt-2020-001394en
dc.description.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/33046595/en
dc.description.affiliatesCentral Coast Local Health Districten
dc.description.affiliatesThe University of Newcastleen
dc.identifier.journaltitleOpen Hearten
dc.type.studyortrialMeta-Analysisen
dc.originaltypeTexten
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.cerifentitytypePublications-
Appears in Collections:Cardiology
Show simple item record

Page view(s)

40
checked on Mar 28, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.